|Bid||96.66 x 1300|
|Ask||96.69 x 900|
|Day's Range||96.30 - 98.62|
|52 Week Range||70.80 - 108.91|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||1,934.80|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.73|
Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $2.58 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Today we'll evaluate Insulet Corporation (NASDAQ:PODD) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in theRead More...
The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months and full year ended December 31, 2018.
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Insulet Corporation (NASDAQ: PODD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 ...
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Daruma Capital Management leader Mariko Gordon (Trades, Portfolio) disclosed she established seven new positions when she released her fourth-quarter 2018 portfolio earlier this week. Warning! GuruFocus has detected 1 Warning Sign with TNDM. Based on these criteria, Gordon's top five new buys for the quarter were Tandem Diabetes Care Inc. (TNDM), Macom Technology Solutions Holdings Inc. (MTSI), Insulet Corp. (PODD), LHC Group Inc. (LHCG) and Cloudera Inc. (CLDR).
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Corinne Nevinny has been appointed to the Company’s Board of Directors, effective immediately. Ms. Nevinny replaces James Mullen, who is stepping down from Insulet’s Board to focus on his family’s philanthropic foundation and other business ventures. Ms. Nevinny is the General Partner of LMNVC, a seed venture fund making early-round investments in start-up companies that have products or services that improve quality of life, including health and wellness oriented businesses.
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2018 on February 25, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 7262247. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
NEW YORK, NY / ACCESSWIRE / January 25, 2019 / U.S. equities were mixed on Thursday as stronger-than-expected quarterly earnings werent enough to outweigh concerns of a global economic slowdown. The Dow ...
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Wayde McMillan has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2019, succeeding Michael Levitz. To ensure a smooth and successful transition, Mr. McMillan will join the Company in February and Mr. Levitz will continue with the Company in an advisory capacity for a period following the succession effective date.